CN105532976A - Strigose hydrangea leaf and herba gynostemmatis pentaphylli compound original tea preparation method - Google Patents
Strigose hydrangea leaf and herba gynostemmatis pentaphylli compound original tea preparation method Download PDFInfo
- Publication number
- CN105532976A CN105532976A CN201510976129.0A CN201510976129A CN105532976A CN 105532976 A CN105532976 A CN 105532976A CN 201510976129 A CN201510976129 A CN 201510976129A CN 105532976 A CN105532976 A CN 105532976A
- Authority
- CN
- China
- Prior art keywords
- tea
- compound
- gynostemma pentaphylla
- sweet tea
- former
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention discloses a strigose hydrangea leaf and herba gynostemmatis pentaphylli compound original tea preparation method. The strigose hydrangea leaves and the herba gynostemmatis pentaphylli are mixed at a weight ratio of (1-2):(1-10), ethanol at a concentration of 60-75v% is added, extraction is conducted under ultrasonic waves, lime water is added into the extract to adjust the pH into 7.6-7.8, the mixture is centrifuged, the supernatant is removed by filtration, and the precipitate is freeze-dried, thereby obtaining the compound original tea. The prepared compound original tea has a synergism on diabetes sugar lowering and has a certain protection function for improving diabetes complication such as abnormal lipid metabolism and kidney damage.
Description
Technical field
The present invention relates to the preparation method of the former tea of a kind of compound, be specifically related to the preparation method of the former tea of compound of a kind of sweet tea and gynostemma pentaphylla.
Background technology
Diabetes are chronic lifelong participation diseases, and along with the raising of people's living standard, its incidence of disease is in the trend risen year by year.In order to control blood sugar, long-term limit sugar diet and drug therapy have also had a strong impact on the quality of life of patient.Sweet tea (RubusSuavissmusSLee) is the leaf of the distinctive natural sweet taste plant in Guangxi, is also Gao Tian best in the world, low-heat, safety non-toxic and have the sweet-tasting plant of health care.In sweet tea about containing the bioflavonoid of 4.1%, the sweet tea tannins of 18.04% and 5% glycosides (Rubusoside).Research finds that glycosides can reduce normal mouse blood sugar level, has obvious inhibitory action to mouse gluconeogenesis.By the hyperglycemic rat gavage that sweet tea extract brings out Streptozotocin, the indexs such as blood sugar, fructosamine, insulin and SOD are surveyed after 3 weeks, find that sweet tea extract can reduce rat blood sugar significantly, strengthen its oxidation resistance, the secretion of insulin can be stimulated to reduce blood sugar simultaneously.
Although prior art discloses sweet tea can be used for the treatment of diabetes separately, the target spot of its effect limits to relatively, effectively cannot prevent and treat the generation of diabetic complication.
Summary of the invention
The technical problem to be solved in the present invention is to provide the preparation method of the former tea of compound of a kind of sweet tea and gynostemma pentaphylla; the former tea of this compound not only has synergy at diabetes blood sugar-reduction formula mask, and to improving diabetic complication Anomalous lipid metablism and kidney injury has certain protective effect.
Technical scheme provided by the invention is the preparation method of the former tea of compound of sweet tea and gynostemma pentaphylla, sweet tea and gynostemma pentaphylla are mixed by 1 ~ 2:1 ~ 10 weight ratio, add the ethanol of 60 ~ 75v%, extract under Ultrasonic Conditions, add limewash toward extract and regulate pH to 7.6 ~ 7.8, centrifugal, elimination supernatant, taking precipitate freeze drying, is the former tea of compound.
Gynostemma pentaphylla (Gynostemmapentaphyllum (Thunb.) Makino) is Curcurbitaceae, the leaf of gynostemma pentaphyllum genus herbaceous stem Climbing Plant, has hypoglycemic, reducing blood lipid and hypotensive effect.
Step 1) in, be the composition such as the polyphenol in the sweet tea of alcohol extract of 60 ~ 75% and the polysaccharide in gynostemma pentaphylla by volumetric concentration.Limewash regulates pH to 7.6 ~ 7.8, can by the polyphenols complex-precipitation in extract.There is multiple ortho positions phenolic hydroxyl group in sweet tea tannins molecule, can be used as multidentate ligand and Ca
2+complexing, forms the chelate of ring-type and produces precipitation, and when pH value is 7.6 ~ 7.8, sweet tea tannins is with the negative oxygen ion of an ionic state and a phenolic hydroxyl group and Ca
2+complexing, or with the negative oxygen ion of two ionic state and Ca
2+complexing, formation be an aglucon complex compound sediment.Meanwhile, under this pH value condition, sweet tea tannins also also form an aglucon complex compound sediment with gynostemma pentaphylla polysaccharide molecule.
Ultrasonic Conditions 1 ~ 3 time, each 1 ~ 2h; Ultrasonic Conditions is: temperature 40 ~ 50 DEG C, frequency are 250 ~ 400Hz.Preferred ultrasonic frequency is 300 ~ 400Hz.During each extraction, the addition of ethanol is 4 ~ 10 times of sweet tea and gynostemma pentaphylla gross weight.
The preferred weight ratio of sweet tea and gynostemma pentaphylla is 1:1.
Former tea of the present invention conveniently technique can be deployed into compound tea, for diabetes patients.
Compared with prior art, the present invention is extracted polyphenol molecule in sweet tea and gynostemma pentaphylla polysaccharide molecule, by sweet tea tannins and Ca
2+complexing generates an aglucon complex compound; and sweet tea tannins and gynostemma pentaphylla polysaccharide molecular complex are formed an aglucon complex compound; the mixture of an above-mentioned aglucon complex compound can play collaborative hypoglycemic effect, and to improving diabetic complication Anomalous lipid metablism and kidney injury has certain protective effect.Empirical tests, the hypoglycemic effect of this mixed complex is far superior to the conventional extract of sweet tea and gynostemma pentaphylla.
Detailed description of the invention
Embodiment 1
Sweet tea and gynostemma pentaphyllum leaf are pressed 1:1 weight ratio co-grinding, add the ethanol of 60v%, the addition of ethanol is 4 times of sweet tea and gynostemma pentaphylla gross weight, 1h is extracted under being the Ultrasonic Conditions of 250Hz in temperature 40 DEG C, frequency, in extract, add limewash regulate pH to 7.6, centrifugal, elimination supernatant, taking precipitate freeze drying, is the former tea of compound.
Reference examples 1
Pulverized by gynostemma pentaphyllum leaf, add the ethanol of 60v%, 4 times of the addition gynostemma pentaphylla weight of ethanol, extract 1h in temperature 40 DEG C, frequency under being the Ultrasonic Conditions of 250Hz, by extract reduced pressure concentration recycling design, freeze drying, is the former tea of gynostemma pentaphylla.
Reference examples 2
Sweet tea is pulverized, adds the water of sweet tea weight 4 times, extract 1h in temperature 40 DEG C, frequency under being the Ultrasonic Conditions of 250Hz, extract is concentrated into medicinal extract, freeze drying, be the former tea of sweet tea.
Embodiment 2
Sweet tea and gynostemma pentaphyllum leaf are pressed 1:10 weight ratio co-grinding, add the ethanol of 75v%, the addition of ethanol is 10 times of sweet tea and gynostemma pentaphylla gross weight, extracts 3 times, each 2h under temperature 50 C, frequency are the Ultrasonic Conditions of 400Hz, merge extract, in extract, add limewash regulate pH to 7.8, centrifugal, elimination supernatant, taking precipitate freeze drying, is the former tea of compound.
Embodiment 3
Sweet tea and gynostemma pentaphyllum leaf are pressed 2:1 weight ratio co-grinding, add the ethanol of 70v%, the addition of ethanol is 6 times of sweet tea and gynostemma pentaphylla gross weight, extracts 2 times, each 1.5h under temperature 45 C, frequency are the Ultrasonic Conditions of 300Hz, merge extract, in extract, add limewash regulate pH to 7.8, centrifugal, elimination supernatant, taking precipitate freeze drying, is the former tea of compound.
Embodiment 4
Sweet tea and gynostemma pentaphyllum leaf are pressed 2:10 weight ratio co-grinding, add the ethanol of 60v%, the addition of ethanol is 10 times of sweet tea and gynostemma pentaphylla gross weight, extract 2h in temperature 40 DEG C, frequency under being the Ultrasonic Conditions of 400Hz, merge extract, in extract, add limewash regulate pH to 7.7, centrifugal, elimination supernatant, taking precipitate freeze drying, is the former tea of compound.
Experimental example
1, the foundation of diabetic mouse model
By the healthy kunming mice 100 of body weight at 18 ~ 22g, male and female half and half, carry out randomly drawing 20 after adaptability feeds one week for blank group, except blank group mouse feeds chow diet, all the other 80 mouse all feed high lipid food, feed equal overnight fasting after 4 weeks, take every Mouse Weight, and according to every Mouse Weight, give abdominal cavity, 80 mouse lower-lefts disposable injection Streptozotocin (STZ) the citric acid-sodium citrate parenteral solution 200mg/kg except blank group, blank group only injects the citric acid-sodium citrate buffer of equal volume.Inject after STZ3 days, fasting 12h, tail venous blood sampling surveys its fasting blood-glucose, and with fasting blood-glucose >=11.1mmol/L is the successful standard of experimental NIDDM Establishment of mouse model.
High lipid food is filled a prescription: basal feed 78.8%, yolk powder 10%, lard 10%, cholesterol 1%, sodium taurocholate 0.2%.
The mouse be successfully established by model is divided into model control group, experimental group, control group 1, control group 2 at random, often organizes 20.Model control group continues to give high lipid food, uses distilled water gavage.All the other each group while giving high lipid food, according to dosage 350mg/kg gives the former tea gavage of embodiment 1, reference examples 1 and reference examples 2 respectively.Every morning 9 gavages, every day 1 time, continuous gavage 12 weeks, fasting 12h after administration in 12nd week, to after every mouse according to dosage 2g/kg glucose gavage at the sugar tolerance that its corresponding time tail venous blood sampling measures, afterwards, weigh the body weight of every mouse, take to pluck eyeball method and get blood 1.5ml, upper serum is drawn after 3500r/min is centrifugal 10 minutes, pick the liver,spleen,kidney of mouse, pancreas, clean with physiological saline and weigh after blotting with clean filter paper to be placed on immediately in-80 DEG C of refrigerators together with serum and preserve, for subsequent use.
2, STZ is caused to the experiment of diabetic mice sugar tolerance
Gavage process is after 12 weeks, the equal fasting 8h of each group mouse, take mouse tail vein to get blood glucose value that blood records as the blood glucose value of 0h, then according to dosage 2g/kg gavage glucose solution, then after gavage 0.5,1,1.5,2h tail venous blood sampling measures blood glucose value.Observe the change of each group of blood sugar concentration on each time point.
3, the mensuration of indices
After diabetic mouse model is successfully established, every day observes the ordinary circumstance of mouse, as chroma of hair, motion frequency, feed inflow, body weight etc.Weigh the body weight of each group of mouse at gastric infusion in 12 weeks on every Fridays morning, and after fasting 12h, adopt tail venous blood sampling to measure the fasting blood sugar of each group of mouse.
3.1 blood preparation indexs
Go eyeball to get blood, the centrifugal 10min of 3500r/min, separation of serum, measure blood sugar (GLU), T-CHOL (TC), triglycerides (TG), serum creatinine (SCr) with full automatic biochemical apparatus; Glycosylated hemoglobin (GHbA1c), biological transforming factor β is measured with ELIASA
1(TGF-β
1).
3.2 urine specimen indexs
Experiment terminates the previous day collects 24h urine, gets 4ml after metering, and the centrifugal 10min of 3000r/min removes sediment, gets 2ml and measures 24h urine micro protein (mALB) and UCr (UCr).
4, experimental result:
The former tea of 4.1 compound causes the impact of diabetic mice fasting blood-glucose in table 1 to STZ:
The former tea of table 1 compound causes the impact of diabetic mice fasting blood-glucose on STZ
Note: each group compares with blank group, * p < 0.05, * * p < 0.01; Each group is compared with model control group, △ p < 0.05, △ △ p < 0.01.
The former tea of 4.2 compound causes the impact of diabetic mice sugar tolerance in table 2 to STZ:
The former tea of table 2 compound causes the impact of diabetic mice sugar tolerance on STZ
From table 1 and table 2, the former tea of experimental group has obvious hypoglycemic activity, improves its sugar tolerance, effectively have adjusted the glycometabolism in diabetic mice.
The former tea of 4.3 compound on STZ cause diabetic mice TC the impact of TG in table 3:
The former tea of table 3 compound on STZ cause diabetic mice TC the impact of TG
| Group | TC(mmol/l) | TG(mmol/l) |
| Blank group | 3.00±0.61△ | 1.15±0.33△ |
| Model control group | 4.72±3.22 | 1.36±0.72 |
| Experimental group | 3.70±1.43△ | 1.16±0.53△ |
| Control group 1 | 4.29±1.37△△ | 1.22±0.65△ 4 --> |
| Control group 2 | 4.18±1.73△ | 1.24±0.85△ |
Note: administration is respectively organized after 12 weeks and compared with model control group, △ p < 0.05, △ △ p < 0.01.
As shown in Table 3, the former tea of compound of experimental group, by reducing cholesterol TC too high in diabetic mice, triacylglycerol TG, strengthen the ability of body lipid-metabolism, and successful is better than control group.
The former tea of 4.4 compound causes diabetic mice TGF-β to STZ
1, mALB, GHbA1c impact in table 4:
The former tea of table 4 compound causes diabetic mice TGF-β to STZ
1, mALB, GHbA1c impact
| Group | TGF-β 1(pg/ml) | mALB(μg/ml) | GHbA1c(ng/ml) |
| Blank group | 6.67±1.21△△ | 1.46±1.02△ | 4.77±1.09△ |
| Model control group | 17.11±1.30 | 19.91±3.61 | 13.77±1.02 |
| Experimental group | 7.28±1.04△ | 7.60±2.70△ | 5.65±1.80△△ |
| Control group 1 | 10.04±1.23△△ | 11.60±2.15△△ | 7.89±0.88△ |
| Control group 2 | 10.91±1.06△ | 10.60±2.70△ | 7.65±1.80△△ |
Note: administration is respectively organized after 12 weeks and compared with model control group, △ p < 0.05, △ △ p < 0.01.
As shown in Table 5, biological transforming factor β 1 is the important factor causing diabetic mice kidney injury, and the former tea of compound of experimental group can reduce the content of biological transforming factor β 1 in diabetic mice significantly, and effect is better than control group.Show that the kidney of experimental group to diabetic mice has protective effect, and certain prevention effect is played to the generation of diabetic nephropathy and development.
The former tea of compound of experimental group can obviously reduce glycated hemoglobin levels in Mice Body, alleviate because glycated hemoglobin levels raises the histanoxia caused to a great extent, alleviate glycated hemoglobin levels raise cause especially occur in the abundant position microangiopathies of kidney tip capilary, and then alleviate and cause histocyte hypoxic-ischemic and tissue damage thus, and then the content of microdose urine protein also significantly reduces.The former tea of compound of experimental group significantly can reduce the content of microdose urine protein and glycosylated hemoglobin in diabetic mice, have certain effect, and successful is better than control group to diabetes and nephropathy preventing.
The former tea of 5.5 compound causes the impact of diabetic mice serum creatinine (SCr) and UCr (UCr) in table 5 to STZ:
The former tea of table 5 compound causes the impact of diabetic mice serum creatinine (SCr) and UCr (UCr) to STZ
| Group | SCr(μmol/l) | UCr(μmol/l) |
| Blank group | 9.43±1.41△△ | 425.77±1.23△ |
| Model control group | 16.91±1.02* | 103.32±1.04** |
| Experimental group | 9.61±1.70**△△ | 221.78±1.20*△ |
| Control group 1 | 10.60±1.15*△ | 161.89±0.98*△△ |
| Control group 2 | 10.73±1.64**△△ | 158.65±1.36**△△ |
Note: administration is respectively organized after 12 weeks and compared with blank group, * p < 0.05, * * p < 0.01; Each group is compared with model control group, △ p < 0.05, △ △ p < 0.01.
As shown in Table 5, serum creatinine and UCr are all the indexs of reflection kidney injury degree.The former tea of experimental group compound can reduce the content of serum creatinine in diabetic mice significantly; and the content of UCr in diabetic mice can be improved significantly; concentration both the former tea of the former tea of illustrative experiment group compound can effectively regulate in diabetic mice; thus reach the effect of protection kidney, and successful is better than control group.
From table 1 ~ table 5, the former tea of compound of experimental group can by reducing cholesterol too high in diabetic mice, triacylglycerol, strengthen the ability of body lipid-metabolism, blood sugar level in remarkable reduction diabetic mice, improve its sugar tolerance, diabetic mice blood can also be improved simultaneously, the content of the UCr in urine, reduce diabetic mice blood, serum creatinine in urine, transforming growth factor-beta 1, microdose urine protein, effect of saccharification hemoglobin content, alleviate the kidney injury of diabetic nephropathy mouse, to the damage of prevention diabetic mice kidney, there is protective effect.
Claims (5)
1. the preparation method of the former tea of the compound of sweet tea and gynostemma pentaphylla, it is characterized in that: sweet tea and gynostemma pentaphylla are mixed by 1 ~ 2:1 ~ 10 weight ratio, add the ethanol of 60 ~ 75v%, extract under Ultrasonic Conditions, add limewash toward extract and regulate pH to 7.6 ~ 7.8, centrifugal, elimination supernatant, taking precipitate freeze drying, is the former tea of compound.
2. the preparation method of the former tea of compound of sweet tea according to claim 1 and gynostemma pentaphylla, is characterized in that: Ultrasonic Conditions 1 ~ 3 time, each 1 ~ 2h; Described Ultrasonic Conditions is: temperature 40 ~ 50 DEG C, frequency are 250 ~ 400Hz.
3. the preparation method of the former tea of compound of sweet tea according to claim 2 and gynostemma pentaphylla, is characterized in that: described ultrasonic frequency is 300 ~ 400Hz.
4. the preparation method of the former tea of compound of the sweet tea according to any one of claims 1 to 3 and gynostemma pentaphylla, is characterized in that: the addition of ethanol is 4 ~ 10 times of sweet tea and gynostemma pentaphylla gross weight.
5. the preparation method of the former tea of compound of the sweet tea according to any one of claims 1 to 3 and gynostemma pentaphylla, is characterized in that: the weight ratio of sweet tea and gynostemma pentaphylla is 1:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510976129.0A CN105532976A (en) | 2015-12-22 | 2015-12-22 | Strigose hydrangea leaf and herba gynostemmatis pentaphylli compound original tea preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510976129.0A CN105532976A (en) | 2015-12-22 | 2015-12-22 | Strigose hydrangea leaf and herba gynostemmatis pentaphylli compound original tea preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105532976A true CN105532976A (en) | 2016-05-04 |
Family
ID=55812977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510976129.0A Pending CN105532976A (en) | 2015-12-22 | 2015-12-22 | Strigose hydrangea leaf and herba gynostemmatis pentaphylli compound original tea preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105532976A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829181A (en) * | 2008-03-31 | 2010-09-15 | 北京市科威华食品工程技术有限公司 | Extract of the effective-part of Gynostemma pentaphyllum and preparation method thereof |
| CN102894123A (en) * | 2011-07-26 | 2013-01-30 | 南通金土地绿色食品有限公司 | Gynostemma pentaphylla sweet tea |
| CN103330019A (en) * | 2013-06-13 | 2013-10-02 | 广西金昊生物科技有限公司 | Gynostemma pentaphylla formulation and preparation method thereof |
-
2015
- 2015-12-22 CN CN201510976129.0A patent/CN105532976A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101829181A (en) * | 2008-03-31 | 2010-09-15 | 北京市科威华食品工程技术有限公司 | Extract of the effective-part of Gynostemma pentaphyllum and preparation method thereof |
| CN102894123A (en) * | 2011-07-26 | 2013-01-30 | 南通金土地绿色食品有限公司 | Gynostemma pentaphylla sweet tea |
| CN103330019A (en) * | 2013-06-13 | 2013-10-02 | 广西金昊生物科技有限公司 | Gynostemma pentaphylla formulation and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张钟等: "绞股蓝多糖的提取及理化性质研究", 《中国林副特产》 * |
| 李鹏婧等: "绞股蓝多糖的提取及咀嚼片的研制", 《食品科技》 * |
| 王昭晶等: "碱提绞股蓝水溶性多糖的研究", 《食品研究与开发》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107080250A (en) | A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof | |
| CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN105381087A (en) | Preparation method of cyclocarya paliurus and Adinandra nitida Merr. ex H. L. Li compounded original tea | |
| CN103223111B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN105030984B (en) | A kind of semen litchi health care oral liquid and preparation method with hypoglycemic, tune rouge and alleviation diabetic complication | |
| CN111919934A (en) | Safflower Suxin tea for reducing high blood pressure, high blood sugar and protecting cardiovascular and preparation method thereof | |
| CN105412222A (en) | Preparation method of sweet tea and cyclocarya paliurus composite original tea | |
| CN110624042B (en) | Composition for treating diabetic diseases | |
| CN103637179A (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN101647951B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN109090604A (en) | A kind of composition with auxiliary hyperglycemic function, health food and preparation method thereof | |
| CN105477370A (en) | Preparing method of sweet-dendrobe combined raw tea | |
| CN103230426B (en) | Medical composition for treating diabetes mellitus and complications thereof | |
| CN101953867B (en) | Petroleum ether extract of saussurea involucrate, application preparation method and application thereof | |
| CN101336965B (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| CN105532976A (en) | Strigose hydrangea leaf and herba gynostemmatis pentaphylli compound original tea preparation method | |
| CN104490993A (en) | Method for preparing cyclocarya paliurus extract with antioxidant activity and application with cyclocarya paliurus extract as aldose reductase inhibitor | |
| CN108260682A (en) | A kind of hypoglycemic, reducing blood lipid and the health protection tea of blood pressure lowering | |
| CN105412168A (en) | Preparation method of sweet tea and gingko composite original tea | |
| CN103566227B (en) | A kind of Chinese medicine composition preventing and treating type 2 diabetes mellitus and preparation method thereof | |
| CN105560328A (en) | Preparation method of Folium Rubi Suavissimi and Radix Isatidis mixed original tea | |
| CN103285027A (en) | Application of chroogomphus rutilus mycelium polysaccharide in preparation of blood sugar reducing medicines | |
| CN105535866A (en) | Medicine for treating hyperlipidemia and preparation method thereof | |
| CN108685964A (en) | The application of pilose gerbera herb extract and its active principle preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160504 |